Who needs more than two employees when artificial intelligence can do so many corporate tasks? It’s super efficient — and a little bit lonely.
Category: GLP-1 RAs (Drug)
-
How A.I. Helped One Man (and His Brother) Build a $1.8 Billion Company
The New York Times – Business: -
Ozempic Is About to Go Generic in India, China and Canada
The New York Times – Business:In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
-
Weight-Loss Drugs Could Save U.S. Airlines $580 Million Per Year
A study by the financial firm Jefferies highlights a surprising perk for carriers: lower fuel costs as slimmer passengers lighten their aircrafts’ loads.
-
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech World
The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.
-
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
-
U.S. Announces Negotiated Prices for 15 Drugs Under Medicare
The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which would have reduced its spending on those drugs by 44 percent.
-
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
-
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.
-
What Trump’s New Drug Pricing Deal Means for People With Obesity
The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.
-
Obesity Drugs May Drop to as Little as $150 a Month
President Trump announced a deal with Eli Lilly and Novo Nordisk to lower prices on hugely popular weight-loss drugs for Medicare, Medicaid and American patients who pay with their own money.